PRESS RELEASE published on 08/06/2024 at 09:01, 1 year 8 months ago Original-Research: LAIQON AG (von NuWays AG): BUY LAIQON AG successfully places LAIC token 24 & intensifies cooperation with mVBRB, leading to total gross proceeds of €7.2m. Additional undisclosed payment to be invested in enhancing DAP 4.0 and personnel development Investments Coopération LAIQON AG LAIC Token MVBRB
PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Northern Data Group announces Q2 Results, reaffirms 2024 guidance Northern Data Group reports Q2 revenue growth of 22% year-on-year to EUR 26 million, reaffirms 2024 revenue target of EUR 200-240 million, driven by Cloud and HPC infrastructure expansion Revenue Growth Northern Data Group 2024 Guidance Q2 Results HPC Solutions
PRESS RELEASE published on 08/06/2024 at 08:31, 1 year 8 months ago Cherry SE Releases 2024 Half-Year Report Cherry SE releases its 2024 Half-Year Report, showing revenue growth in DIGITAL HEALTH & SOLUTIONS segment and confirmed forecasts for 2024 Revenue Growth Cherry SE Forecasts 2024 Half-Year Report DIGITAL HEALTH & SOLUTIONS
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant son avancement vers l'objectif de recrutement complet au premier trimestre 2025 Abivax Recrutement Essai Clinique Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant l'évolution favorable du projet. La société réaffirme ses prévisions pour 2025 Abivax Recrutement Traitement Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 29/07/2024 tot 02/08/2024 Cie du Bois Sauvage voert terugkoop van eigen aandelen uit zoals gemachtigd door de buitengewone algemene vergadering van 28 april 2021 NYSE Euronext Brussel Financiële Informatie Cie Du Bois Sauvage Terugkoop Eigen Aandelen Buitengewone Algemene Vergadering
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage : Rachat d’actions propres – semaine du 29/07/2024 au 02/08/2024 La Compagnie du Bois Sauvage annonce le rachat de 655 actions propres sur le marché réglementé NYSE Euronext Bruxelles, conformément à l'autorisation de l'AG du 28/04/2021 Rachat D'actions NYSE Euronext Bruxelles Compagnie Du Bois Sauvage Transactions Actions Propres Autorisation AG
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Buy back of own shares – week from 29/07/2024 to 02/08/2024 Compagnie du Bois Sauvage announces buy back of own shares from 29/07/2024 to 02/08/2024, totaling €179,277.00. Details available on www.bois-sauvage.be NYSE Euronext Market Brussels Financial Transactions Own Shares Compagnie Du Bois Sauvage Buy Back
Published on 04/22/2026 at 01:55, 2 hours 48 minutes ago Immutable Holdings Announces Director Resignation
Published on 04/22/2026 at 01:30, 3 hours 13 minutes ago Challenger West Assays Return Grades up to 60g/t Au
Published on 04/22/2026 at 00:00, 4 hours 43 minutes ago Zimtu Capital Corp. and Global Energy Metals Corporation Agree to Terminate Option Agreement for the Monument Peak Copper-Silver Project, Idaho
Published on 04/22/2026 at 00:00, 4 hours 43 minutes ago Grande Portage Resources Announces SEDAR+ Filing of Preliminary Economic Assessment (PEA) Study for the New Amalga Gold Project in SE Alaska
Published on 04/21/2026 at 22:15, 6 hours 28 minutes ago Amrize Shareholders Approve All Proposals at 2026 Annual General Meeting
Published on 04/21/2026 at 20:50, 7 hours 53 minutes ago CATL Unveils Six Major Innovations: Multi-Chemistry Systems to Redefine New Energy Mobility Experience
Published on 04/21/2026 at 19:15, 9 hours 28 minutes ago Shelly Group SE publishes 2025 Investors Report as an established transparency format
Published on 04/21/2026 at 19:08, 9 hours 35 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/21/2026 at 19:02, 9 hours 41 minutes ago Brockhaus Technologies AG: Actions for annulment and nullity against the approval resolution of the Extraordinary General Meeting of February 26, 2026
Published on 04/21/2026 at 19:15, 9 hours 28 minutes ago AXA - Description of the Company’s share repurchase program
Published on 04/21/2026 at 19:15, 9 hours 28 minutes ago AXA - Descriptif du programme de rachat d’actions
Published on 04/21/2026 at 18:00, 10 hours 43 minutes ago Outstanding shares and voting rights statement at 31 March 2026
Published on 04/21/2026 at 18:00, 10 hours 43 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 mars 2026
